Analysis of innate and acquired resistance to anti-CD20 antibodies in malignant and nonmalignant B cells
The anti-CD20 monoclonal antibody, rituximab, provides a significant therapeutic benefit for patients with B-cell disorders. However, response to therapy varies and relapses are common, so an understanding of both inherited and acquired rituximab resistance is needed. In order to identify mechanisms...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
PeerJ Inc.
2013-02-01
|
Series: | PeerJ |
Subjects: | |
Online Access: | https://peerj.com/articles/31.pdf |